Yong-cheng Wang

Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes

R. Pazdur, Atiqur Rahman, A. Farrell, 2005, Clinical Cancer Research.

FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.

Richard Pazdur, Rajeshwari Sridhara, R. Pazdur, 2005, The oncologist.

Report from the Food and Drug Administration Pemetrexed in Malignant Pleural Mesothelioma

Robert M. White, R. Pazdur, J. Gobburu, 2005 .

Pemetrexed in malignant pleural mesothelioma.

Robert M. White, R. Pazdur, J. Gobburu, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer.

R. Pazdur, R. Sridhara, Martin H. Cohen, 2005, The oncologist.

Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma

R. Pazdur, J. Gobburu, R. Lostritto, 2004, Clinical Cancer Research.

Report from the FDA Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma

R. Pazdur, J. Gobburu, R. Lostritto, 2004 .

Pulmonary Benign Metastasizing Leiomyoma and Review the Imaging Presentation

Shih-hung Huang, Hsio-yun Chang, Yong-cheng Wang, 2012 .

A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.

C. Hamilton, T. Sterling, A. Vernon, 2002, American journal of respiratory and critical care medicine.